Evonik's Cash Machine Runs Hot, but Two Brokerages Still Won't Buy the Story
Published on 11/05/2026 at 15:12 | Editorial boerse-global.de
Evonik's third-quarter figures landed with force this week — a 40% surge in adjusted EBITDA to EUR 629 million and a free cash flow of EUR 369 million — yet the market's professional graders responded with a split verdict that says as much about valuation as about performance. Two houses raised their price targets on Wednesday. Neither moved to a buy.
JPMorgan lifted its target to EUR 15 from EUR 14 while keeping its "Underweight" rating, a combination that signals caution rather than conviction. Berenberg took a more generous view of the same numbers, pushing its target to EUR 22.50 from EUR 20 but holding firm on "Hold." At a share price of EUR 21.48, Evonik trades above JPMorgan's mark and below Berenberg's — a spread that leaves investors without a single, coherent signal on where the stock should settle.
The divergence matters because it separates two questions that are easily blurred: what a company earns, and what its shares are worth. Both brokerages revised their targets in the wake of Tuesday's quarterly release. Only one of them, in effect, sees meaningful headroom from here.
A Business Improving Faster Than Its Top Line
The operating picture behind those revisions is genuinely brighter. Revenue for the third quarter of 2026 climbed 13% to EUR 3.825 billion, while adjusted EBITDA grew considerably faster — evidence that margins, not just volume, are doing the work. Management now expects full-year adjusted EBITDA in the upper half of its guidance range of EUR 2.0 billion to EUR 2.2 billion. That remains a forecast, not a banked result.
Should investors sell immediately? Or is it worth buying Evonik?
Cash generation tells a similar story from a different angle. The EUR 369 million free cash flow recorded in the quarter brought the nine-month total to EUR 601 million, and Evonik is guiding toward roughly EUR 850 million for the full year. For shareholders weighing the standalone case, that figure carries weight: it demonstrates the group's capacity to fund itself, independent of any outside interest.
The Standalone Argument, Stated in Public
That independence is not merely a financial abstraction. Finance chief Michael Rauch used Tuesday's platform to describe the timing of BASF's takeover ambitions as "really odd," doubling down on a position the executive board had already staked out on 30 October, when it rejected negotiations over BASF's interest in a voluntary public takeover offer. Evonik left one door ajar — a purely informational, confidential exchange — but drew a clear line between talking and negotiating.
The strategic tension extends beyond the parent company. Reuters reported on 27 October that Thomas Basten, spokesperson for the management of the divestment candidate Syneqt, called independence for the Evonik subsidiary strategically sensible. BASF, for its part, has said it can operate the Marl and Wesseling chemical parks itself. Those competing visions of how the infrastructure should be run remain unresolved — and the latest quarterly numbers do nothing to settle them.
Evonik at a turning point? This analysis reveals what investors need to know now.
Two Clocks Running at Once
Alongside the takeover question, Evonik's portfolio work continues on schedule. The company confirmed Tuesday that the sales process for Oxeno, its C4 chemicals unit, is proceeding as planned — a process in motion, not a completed transaction.
What emerges is a company making its case on two fronts simultaneously: operational momentum on one side, structural reshaping on the other. The analyst reaction suggests the first is being acknowledged while the second is being priced with restraint. Higher targets, after all, are not the same as recommendations to buy — and anyone valuing Evonik shares right now has to hold three things apart: the earnings trajectory, the target price, and the rating attached to it.
Ad
Evonik Stock: New Analysis - 5 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
